Transdermal iontophoresis of rotigotine: Influence of concentration, temperature and current density in human skin in vitro

Journal of Controlled Release

Volumn 96, Issue 1, 2004, Pages 159-167

  Nugroho, Akhmad Kharis ^a,b   Li, Gailing ^a   Grossklaus, Arne ^a   Danhof, Meindert ^a   Bouwstra, Joke A ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b GADJAH MADA UNIVERSITY   (Indonesia)

Author keywords

Dermatomed human skin; DHS; Dopamine receptor agonist; Electro repulsion; Estimated steady state flux; Fluxss; HSC; Human stratum corneum; Parkinson's disease; Tetra butyl ammonium; Tetra ethyl ammonium

Indexed keywords

CELLS; CONCENTRATION (PROCESS); CURRENT DENSITY; DIFFUSION; THERMAL EFFECTS; TITRATION;

HUMAN STRATUM CORNEUM (HSC);

SKIN;

ROTIGOTINE; SODIUM ION; TETRABUTYLAMMONIUM; TETRYLAMMONIUM;

ADULT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DENSITY; DERMATOME; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG TRANSPORT; ELECTRIC CURRENT; FEMALE; HUMAN; HUMAN TISSUE; IONTOPHORESIS; MOLECULAR WEIGHT; PH; PRIORITY JOURNAL; ROOM TEMPERATURE; SKIN PENETRATION; SKIN TEMPERATURE; STEADY STATE; STRATUM CORNEUM; TEMPERATURE DEPENDENCE; TITRIMETRY;

ADMINISTRATION, CUTANEOUS; ADULT; FEMALE; HUMANS; IONTOPHORESIS; MIDDLE AGED; SKIN; TEMPERATURE; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 1842473796     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2004.01.012     Document Type: Article

References (24)

1. Swart P.J., de Zeeuw R.A. Pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in freely moving rats. J. Pharm. Sci. 82:1993;200-203.
2. Swart P.J., de Zeeuw R.A. Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats. Pharmazie. 47:1992;613-615.
3. Swart P.J., Oelen W.E., Bruins A.P., Tepper P.G., de Zeeuw R.A. Determination of the dopamine D2 agonist N-0923 and its major metabolites in perfused rat livers by HPLC-UV-atmospheric pressure ionization mass spectrometry. J. Anal. Toxicol. 18:1994;71-77.
4. Gerding T.K., Drenth B.F., Roosenstein H.J., de Zeeuw R.A., Tepper P.G., Horn A.S. The metabolic fate of the dopamine agonist 2-(N-propyl-N-2- thienylethylamino)-5-hydroxytetralin in rats after intravenous and oral administration: I. Disposition and metabolic profiling. Xenobiotica. 20:1990;515-524.
5. Gerding T.K., Drenth B.F., de Zeeuw R.A., Tepper P.G., Horn A.S. The metabolic fate of the dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5- hydroxytetralin in rats after intravenous and oral administration: II. Isolation and identification of metabolites. Xenobiotica. 20:1990;525-536.
6. Calabrese V.P., Lloyd K.A., Brancazio P., Cefali E., Martin P., Wall J.J., Sica D. N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism. Mov. Disord. 13:1998;768-774.
7. Hutton J.T., Metman L.V., Chase T.N., Juncos J.L., Koller W.C., Pahwa R., LeWitt P.A., Samii A., Tsui J.K., Calne D.B., Waters C.H., Calabrese V.P., Bennett J.P., Barrett R., Morris J.L. Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov. Disord. 16:2001;459-463.
8. Metman L.V., Gillespie M., Farmer C., Bibbiani F., Konitsiotis S., Morris M., Shill H., Bara-Jimenez W., Mouradian M.M., Chase T.N. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin. Neuropharmacol. 24:2001;163-169.
9. Sage B.H. Iontophoresis. Smith E.W., Maibach H.I. Percutaneous Penetration Enhancer. 1995;351-368 CRC Press, Boca Raton.
10. Nugroho A.K., Li G.L., Danhof M., Bouwstra J.A. Transdermal iontophoresis of rotigotine across human stratum corneum in vitro: influence of pH and NaCl concentration. Pharm. Res. 2004;. (in press).
11. Van der Geest R., Danhof M., Bodde H.E. Validation and testing of a new iontophoretic continuous flow through transport cell. J. Control. Release. 51:1998;85-91.
12. Kanikkannan N., Singh J., Ramarao P. In vitro transdermal iontophoretic transport of timolol maleate: effect of age and species. J. Control. Release. 71:2001;99-105.
13. Oh S.Y., Jeong S.Y., Park T.G., Lee J.H. Enhanced transdermal delivery of AZT (Zidovudine) using iontophoresis and penetration enhancer. J. Control. Release. 51:1998;161-168.
14. Hirvonen J., Guy R.H. Iontophoretic delivery across the skin: electroosmosis and its modulation by drug substances. Pharm. Res. 14:1997;1258-1263.
15. Delgado-Charro M.B., Rodriguez-Bayon A.M., Guy R.H. Iontophoresis of nafarelin: effects of current density and concentration on electrotransport in vitro. J. Control. Release. 35:1995;35-40.
16. Hoogstraate A.J., Srinivasan V., Sims S.M., Higuchi W.I. Iontophoretic enhancement of peptides: behaviour of leuprolide versus model permeants. J. Control. Release. 31:1994;41-47.
17. Luzardo-Alvarez A., Delgado-Charro M.B., Blanco-Mendez J. Iontophoretic delivery of ropinirole hydrochloride: effect of current density and vehicle formulation. Pharm. Res. 18:2001;1714-1720.
18. Li G.L., Danhof M., Bouwstra J.A. Iontophoretic delivery of apomorphine in vitro: physicochemic considerations. Pharm. Res. 18:2001;1509-1513.
19. Martin A.N., Bustamante P. Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences. 1993;362-392 Lea & Febiger, Philadelphia.
20. Krill S.L., Knutson K., Higuchi W.I. The stratum corneum lipid thermotropic phase behavior. Biochim. Biophys. Acta. 1112:1992;281-286.
21. Bouwstra J.A., de Graaff A., Gooris G.S., Nijsse J., Wiechers J.W., van Aelst A.C. Water distribution and related morphology in human stratum corneum at different hydration levels. J. Invest. Dermatol. 120:2003;750-758.
22. G.L. Li. Transdermal iontophoretic delivery of R-apomorphine for the treatment of patients with Parkinson's Disease, PhD thesis, Leiden University, Leiden, The Netherlands, 2003.
23. Van der Geest R., Danhof M., Bodde H.E. Iontophoretic delivery of apomorphine: I. In vitro optimization and validation. Pharm. Res. 14:1997;1798-1803.
24. Phipps J.B., Gyory J.R. Transdermal ion migration. Adv. Drug Deliv. Rev. 9:1992;137-176.